Biospecimen and Pathology Core

摘要：生物标本和病理学核心 生物标本和病理核心的目的是提供生物标本和病理服务， 支持两个计划中的Li-CAD P20项目以及在 发展研究计划，并准备P50孢子扩大服务。生物标本 Core提供解释基于组织的检测的专业知识，特别是在生物标志物的背景下 研究，确保生物标本的质量标准和道德使用，并提供核心服务， 组织学、数字组织学、免疫组织化学和显微解剖。 SA 1.提供项目1和项目2所需的AI/AN肝病患者的生物标本， 肝硬化和HCC，以及适当的非AI/AN比较/对照患者 我们的Li-CAD项目将从以下来源获得血浆、血清、肝组织和HCC组织标本 支持Li-CAD P20研究的生物储存库：1）一个真正卓越和独特的生物标本库， 来自阿拉斯加原住民（AN）慢性肝病患者（“AN生物储存库”）的样本 部落健康联盟（ANTHC）; 2）来自美国印第安人（AI）患者的生物样本库， 来自切罗基国家卫生服务（CNHS）（“AI生物储存库”）的慢性肝病;和3）两个大的 非AI/AN、多种族/多民族生物储存库，将提供来自非AI/AN的比较标本 患者 AN生物储存库包括> 40，000个前瞻性和纵向收集的生物标本，来自>3500个 ANTHC（Anchorage，AK）肝病和肝炎项目的患者。这是由布莱恩博士指导的 McMahon，Li-CAD生物样本核心的PI和P20 Li-CAD的共同PI，这将有助于简化 为Li-CAD研究者提供这些生物标本。来自这些生物储存库的生物标本将支持 项目1和2，以及未来的发展研究项目和扩大的P50项目 SA 2.扩大美国印第安人肝病、肝硬化和 HCC总部设在切罗基国家卫生服务（CNHS，Tahlequah，OK），并在我们现有的模式， ANTHC的阿拉斯加土著患者的大型生物储存库。 我们将通过一种新的方法， 与切罗基国家卫生服务（CNHS）合作。我们将利用阿拉斯加原住民的专业知识 在CNHS为美国印第安人患者建立类似的肝病生物储存库。这 将是一个宝贵的资源，特别是当我们扩展到P50孢子。 SA 3.提供组织学、数字组织学、免疫组织化学和 Li-CAD研究者的显微解剖

ABSTRACT: BIOSPECIMEN AND PATHOLOGY CORE The purpose of the Biospecimen and Pathology Core is to provide biospecimens and pathology services to support the two planned Li-CAD P20 Projects and those research studies proposed in the context of the Developmental Research Program and to prepare for a P50 SPORE expansion of services. The Biospecimen Core provides expertise in the interpretation of tissue-based assays especially in the context of biomarker studies, ensures quality standards and the ethical use of biospecimens and provides Core services in histology, digital histology, immunohistochemistry and microdissection for Li-CAD investigators. SA1. Provide biospecimens needed for Projects 1 and 2 from AI/AN patients with liver disease, cirrhosis and HCC, as well as from appropriate non-AI/AN comparison/control patients Our Li-CAD project will obtain plasma, serum, liver tissue and HCC tissue specimens from the following biorepositories that will support the Li-CAD P20 studies: 1) a truly remarkable and unique biospecimen bank of samples from Alaska Native (AN) patients with chronic liver disease (“AN biorepository”) from the Alaska Native Tribal Health Consortium (ANTHC); 2) a biospecimen bank of samples from American Indian (AI) patients with chronic liver disease from the Cherokee Nation Health Service (CNHS) (“AI biorepository”) ; and 3) two large non-AI/AN, multiracial/multiethnic biorepositories, that will provide comparison specimens from non-AI/AN patients. The AN biorepository includes >40,000 prospectively and longitudinally collected biospecimens from >3500 patients at the Liver Disease and Hepatitis Program of the ANTHC (Anchorage, AK). This is directed by Dr. Brian McMahon, the PI of the Li-CAD Biospecimen Core and co-PI of the P20 Li-CAD, which will serve to streamline access to these biospecimens for Li-CAD investigators. Biospecimens from these biorepositories will support Projects 1 and 2, as well as future developmental research projects and expanded P50 projects SA2. Expand the biospecimen repository of American Indian patients with liver disease, cirrhosis and HCC based at Cherokee Nation Health Service (CNHS, Tahlequah, OK) and pattern it after our existing, large biorepository of Alaska Native patients at ANTHC. We will augment our biospecimens and patient recruitment from American Indian patients by a new collaboration with Cherokee Nation Health Service (CNHS). We will use our expertise from Alaska Native biorepositories to establish analogous liver disease biorepositories for American Indian patients at CNHS. This will be an invaluable resource, especially as we expand to a P50 SPORE. SA3. Provide core pathology resources in histology, digital histology, immunohistochemistry and microdissection for Li-CAD investigators